The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays

International Journal of Laboratory Hematology

Volumn 37, Issue 4, 2015, Pages e81-e84

  Kim, Y A ^a   Gosselin, R ^b   Van Cott, E M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; DABIGATRAN; FIBRINOGEN; FRESH FROZEN PLASMA; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; ANTICOAGULANT AGENT;

BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FALSE POSITIVE RESULT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; BLOOD CELL; CELL CULTURE; DRUG EFFECTS; LABORATORY DIAGNOSIS; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTICOAGULANTS; ANTITHROMBINS; BLOOD CELLS; BLOOD COAGULATION; CELLS, CULTURED; DABIGATRAN; FALSE POSITIVE REACTIONS; FIBRINOGEN; HUMANS; INTERNATIONAL NORMALIZED RATIO; LUPUS COAGULATION INHIBITOR; PROTEIN C; PROTEIN S; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBIN TIME;

EID: 84948097109     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12319     Document Type: Letter

References (8)

1. Cardiology ACo. Cardiologists rapidly increase dabigatran prescriptions. CardioSource. Available at: http://www.cardiosource.org/News-Media/Publications/Cardiology-Magazine/US-Trends-Dabigatran.aspx. Accessed June 17, 2013.
2. Kitchen S, Gray E, Mackie I, Baglin T, Makris M. on behalf of the BCSH committee. Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol 2014;166:830-41.
3. van Ryn J, Haertter S, Stangier J, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
4. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8.
5. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013;11:1493-502.
6. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007;98:234-42.
7. Adcock DM, Gosselin R, Kitchen S, Dwyre DM. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 2013;139:102-9.
8. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9:2168-75.